Organogenesis Inc. · Canton, MA United States
Company Description
View Organogenesis Inc. Locations On A US Map
This link will open in a new window
This link will open in a new window Organogenesis has the skinny on replacement tissue. Flagship product Apligraf is a human skin substitute approved to treat diabetic foot ulcers and venous leg ulcers caused by poor circulation. Rejection-resistant Apligraf is bio-engineered using living skin cells and has been used to treat chronic open wounds in some 200,000 patients; the company is developing a next-generation version of the material (using its VCT technology) using all human components. In addition to Apligraf, Organogenesis offers a line of biomaterials used in a range of surgical procedures to seal or reconstruct soft tissue, and it also develops regenerative technologies in the area of cosmetic skin rejuvenation. To read the full description, subscribe now.
Call Now at 866-464-3202 or Click here for a Free Hoover's Trial!
Key Organogenesis Inc. Financials
| Company Type | Private Headquarters |
| Fiscal Year-End | December |
| Employees | 182 |
Organogenesis Inc. Executives
13 executives listed for Organogenesis Inc.'s Canton, MA location.
| Title | Name & Bio | Contact |
| President and CEO | Geoff MacKay | Network |
| EVP, COO, and CFO | Gary Gillheeney | Network |
| VP Research | Vincent Ronfard | Network |
Competition
Competitive Landscape for Organogenesis Inc.
Demand is driven by population demographics and advances in medical knowledge and technology. The profitability of individual companies depends on the ability to develop superior products. Large companies have economies of scale in manufacturing and R&D. Small companies can compete successfully by specializing in a particular market segment, or through technical innovation. To read the full description, subscribe now.Top Organogenesis Inc. Competitors
Call Now at 866-464-3202 or Click here for a Free Hoover's Trial!